MCID: HDG003
MIFTS: 33

Hodgkin's Lymphoma, Lymphocytic Depletion

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Hodgkin's Lymphoma, Lymphocytic Depletion

MalaCards integrated aliases for Hodgkin's Lymphoma, Lymphocytic Depletion:

Name: Hodgkin's Lymphoma, Lymphocytic Depletion 12 15
Hodgkin's Lymphocytic Depletion of Unspecified Site 12
Classic Hodgkin Lymphoma, Lymphocyte-Depleted Type 58
Lymphocyte-Depleted Classical Hodgkin Lymphoma 12
Hodgkin's Disease, Lymphocytic Depletion 12
Hodgkin Lymphoma, Lymphocyte Depletion 12

Characteristics:

Orphanet epidemiological data:

58

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:8628
ICD9CM 34 201.7
MeSH 43 D006689
NCIt 49 C9283
ICD10 32 C81.3
ICD10 via Orphanet 33 C81.3
UMLS via Orphanet 72 C0152267
Orphanet 58 ORPHA98846
UMLS 71 C0152267

Summaries for Hodgkin's Lymphoma, Lymphocytic Depletion

MalaCards based summary : Hodgkin's Lymphoma, Lymphocytic Depletion, also known as hodgkin's lymphocytic depletion of unspecified site, is related to lymphoma, hodgkin, classic and marginal zone b-cell lymphoma. An important gene associated with Hodgkin's Lymphoma, Lymphocytic Depletion is LDHAL6B (Lactate Dehydrogenase A Like 6B), and among its related pathways/superpathways are NF-kappaB Signaling and B Cell Development Pathways. The drugs Dexamethasone acetate and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and breast, and related phenotypes are hematopoietic system and immune system

Related Diseases for Hodgkin's Lymphoma, Lymphocytic Depletion

Diseases related to Hodgkin's Lymphoma, Lymphocytic Depletion via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 113)
# Related Disease Score Top Affiliating Genes
1 lymphoma, hodgkin, classic 30.3 TNFRSF8 PTPRC POU2AF1 PAX5 CSF2 CD68
2 marginal zone b-cell lymphoma 30.3 TNFRSF8 PAX5 IGHV4-38-2 CD79A
3 hodgkin's granuloma 10.8
4 methotrexate-associated lymphoproliferation 10.5 POU2AF1 LDHAL6B
5 nodular lymphocyte predominant hodgkin lymphoma 10.5 TNFRSF8 PAX5
6 submandibular adenitis 10.5 TNFRSF8 PAX5
7 selective igg deficiency disease 10.4 PAX5 CD79A
8 monoclonal paraproteinemia 10.4 PAX5 CD79A
9 american histoplasmosis 10.4 TNFRSF8 CD2AP
10 alk-positive anaplastic large cell lymphoma 10.4 TNFRSF8 ALK
11 infected hydrocele 10.4 TNFRSF8 CD79A
12 gastrointestinal lymphoma 10.4 TNFRSF8 CD79A
13 cerebral lymphoma 10.4 TNFRSF8 CD79A
14 glomerular disease 10.4 CD79A CD2AP
15 lymphomatoid papulosis 10.3 TNFRSF8 ALK
16 extraosseous ewings sarcoma-primitive neuroepithelial tumor 10.3 TNFRSF8 PTPRC
17 epiglottis neoplasm 10.3 PTPRC CD79A
18 uterus leiomyosarcoma 10.3 TNFRSF8 FUT4
19 testicular lymphoma 10.3 TNFRSF8 CD79A
20 autoimmune lymphoproliferative syndrome, type v 10.3 TNFRSF8 ALK
21 adult lymphoma 10.3 TNFRSF8 ALK
22 epididymis adenocarcinoma 10.3 PTPRC FUT4
23 epididymis cancer 10.3 PTPRC FUT4
24 t-cell lymphoma, subcutaneous panniculitis-like 10.3 TNFRSF8 ALK
25 t-cell/histiocyte rich large b cell lymphoma 10.3 TNFRSF8 CD68
26 primary cutaneous anaplastic large cell lymphoma 10.3 PTPRC ALK
27 hodgkin's lymphoma, nodular sclerosis 10.3 TNFRSF8 LDHAL6B FUT4
28 langerhans cell sarcoma 10.3 TNFRSF8 CD68
29 reticulum cell sarcoma 10.3 TNFRSF8 PTPRC
30 lymphosarcoma 10.3 TNFRSF8 PTPRC
31 sarcomatoid transitional cell carcinoma 10.3 CD68 ALK
32 lung lymphoma 10.3 TNFRSF8 PAX5 CD79A
33 paranasal sinus lymphoma 10.3 TNFRSF8 PAX5 CD79A
34 intravascular fasciitis 10.3 CD68 ALK
35 urethra clear cell adenocarcinoma 10.3 FUT4 ALK
36 esophageal tuberculosis 10.3 CD68 ALK
37 mental retardation, autosomal dominant 33 10.2 PAX5 IGHV4-38-2
38 spherocytosis, type 4 10.2 POU2AF1 PAX5 IGHV4-38-2
39 adult xanthogranuloma 10.2 FUT4 CD68
40 pleural lipoma 10.2 TNFRSF8 FUT4 ALK
41 pleural empyema 10.2 TNFRSF8 CD79A
42 intraocular lymphoma 10.2 PAX5 IGHV4-38-2
43 tracheal lymphoma 10.2 TNFRSF8 PAX5 IGHV4-38-2
44 breast lymphoma 10.2 TNFRSF8 CD79A ALK
45 glomeruloid hemangioma 10.2 PTPRC CD68
46 spinal cord lymphoma 10.2 PAX5 IGHV4-38-2 CD79A
47 hodgkin's lymphoma, lymphocytic-histiocytic predominance 10.2 TNFRSF8 PTPRC FUT4
48 cll/sll 10.2 PAX5 IGHV4-38-2 CD79A
49 viral esophagitis 10.2 CD79A CD68
50 lymphoma 10.2

Graphical network of the top 20 diseases related to Hodgkin's Lymphoma, Lymphocytic Depletion:



Diseases related to Hodgkin's Lymphoma, Lymphocytic Depletion

Symptoms & Phenotypes for Hodgkin's Lymphoma, Lymphocytic Depletion

MGI Mouse Phenotypes related to Hodgkin's Lymphoma, Lymphocytic Depletion:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.96 C3 CD2AP CD68 CD79A CSF2 FUT4
2 immune system MP:0005387 9.85 C3 CD2AP CD68 CD79A CSF2 FUT4
3 neoplasm MP:0002006 9.43 ALK CD79A CSF2 CYGB PAX5 PTPRC
4 renal/urinary system MP:0005367 9.17 C3 CD2AP CD79A CSF2 CYGB POU2AF1

Drugs & Therapeutics for Hodgkin's Lymphoma, Lymphocytic Depletion

Drugs for Hodgkin's Lymphoma, Lymphocytic Depletion (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 46)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
2
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
3
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
4
Ichthammol Approved Phase 3 8029-68-3
5
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
6
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
7
Lenograstim Approved, Investigational Phase 3 135968-09-1
8
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
9
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
10
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
11
Etoposide Approved Phase 3 33419-42-0 36462
12
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
13
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
14
Cortisone Experimental Phase 3 53-06-5 222786
15
Emodepside Investigational, Vet_approved Phase 3